{
    "clinical_study": {
        "@rank": "136399", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in\n      direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate\n      dehydrogenase deficiency in infants living in Greece.\n\n      II.  Assess the safety of tin mesoporphyrin in high-risk newborns."
        }, 
        "brief_title": "Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia", 
        "condition": [
            "Glucosephosphate Dehydrogenase Deficiency", 
            "Hyperbilirubinemia", 
            "Hemolytic Disease of Newborn"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Erythroblastosis, Fetal", 
                "Hyperbilirubinemia", 
                "Hemolysis", 
                "Hyperbilirubinemia, Neonatal", 
                "Glucosephosphate Dehydrogenase Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients are stratified by gestational age and sex, and randomly assigned\n      in pairs per stratum.\n\n      One group receives a preventive dose of tin mesoporphyrin. Another group receives a\n      therapeutic dose of tin mesoporphyrin according to the plasma bilirubin concentration.\n\n      Patients in either group may be treated concurrently with phototherapy or exchange\n      transfusion if clinically indicated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Hyperbilirubinemia associated with either of the following:\n        Direct Coombs' test-positive ABO hemolytic disease of the newborn Glucose-6-phosphate\n        dehydrogenase deficiency --Prior/Concurrent Therapy-- No maternal phenobarbital in last\n        month of pregnancy --Patient Characteristics-- Performance status: Not specified\n        Hematopoietic: Not specified Hepatic: Not specified Renal: No congenital renal abnormality\n        Cardiovascular: No congenital heart abnormality Pulmonary: No asphyxia requiring assisted\n        ventilation at delivery Other: Gestational age more than 210 days Birth weight at least\n        1500 g No other major congenital abnormality, i.e.: Central nervous system Chromosomal\n        Gastrointestinal No evident or suspected congenital infection, e.g.: Cytomegalovirus\n        Herpes Rubella Syphilis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Hours", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004381", 
            "org_study_id": "199/12021", 
            "secondary_id": "RUH-0330795A"
        }, 
        "intervention": {
            "intervention_name": "tin mesoporphyrin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tin mesoporphyrin"
        }, 
        "keyword": [
            "glucose-6-phosphate dehydrogenase deficiency", 
            "hematologic disorders", 
            "hemolytic disease", 
            "hyperbilirubinemia", 
            "neonatal disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "New England Medical Center Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021-6399"
                    }, 
                    "name": "Rockefeller University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Rockefeller University", 
            "last_name": "Attallah Kappas", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004381"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Rockefeller University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2003"
    }, 
    "geocoordinates": {
        "New England Medical Center Hospital": "42.358 -71.06", 
        "Rockefeller University Hospital": "40.714 -74.006"
    }
}